BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17090397)

  • 1. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays.
    De Juan BS; Von Briesen H; Gelperina SE; Kreuter J
    J Drug Target; 2006 Nov; 14(9):614-22. PubMed ID: 17090397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles.
    Duan J; Mansour HM; Zhang Y; Deng X; Chen Y; Wang J; Pan Y; Zhao J
    Int J Pharm; 2012 Apr; 426(1-2):193-201. PubMed ID: 22274587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.
    Ambruosi A; Gelperina S; Khalansky A; Tanski S; Theisen A; Kreuter J
    J Microencapsul; 2006 Aug; 23(5):582-92. PubMed ID: 16980278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
    Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
    Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity and apoptotic gene expression in an in vitro model of the blood-brain barrier following exposure to poly(butylcyanoacrylate) nanoparticles.
    Hall AM; Hemmer R; Spaulding R; Wetzel HN; Curcio J; Sabel BA; Henrich-Noack P; Pixley S; Hopkins T; Boyce RL; Schultheis PJ; Haik KL
    J Drug Target; 2016 Aug; 24(7):635-44. PubMed ID: 26707984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein inhibition of drug resistant cell lines by nanoparticles.
    Singh MS; Lamprecht A
    Drug Dev Ind Pharm; 2016; 42(2):325-31. PubMed ID: 26065532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles.
    Zhang Y; Yu J; Zhang L; Cai J; Cai D; Lv C
    Tumour Biol; 2016 Feb; 37(2):2703-8. PubMed ID: 26404136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.
    Gelperina SE; Khalansky AS; Skidan IN; Smirnova ZS; Bobruskin AI; Severin SE; Turowski B; Zanella FE; Kreuter J
    Toxicol Lett; 2002 Jan; 126(2):131-41. PubMed ID: 11751017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.
    Petri B; Bootz A; Khalansky A; Hekmatara T; Müller R; Uhl R; Kreuter J; Gelperina S
    J Control Release; 2007 Jan; 117(1):51-8. PubMed ID: 17150277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.
    Ambruosi A; Khalansky AS; Yamamoto H; Gelperina SE; Begley DJ; Kreuter J
    J Drug Target; 2006 Feb; 14(2):97-105. PubMed ID: 16608736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOX-loaded PEG-PLGA and Pluronic copolymer composite micelles enhances cytotoxicity and the intracellular accumulation of drug in DOX-resistant tumor cells.
    Diao YY; Han M; Ding PT; Chen DW; Gao JQ
    Pharmazie; 2010 May; 65(5):356-8. PubMed ID: 20503928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies.
    Zhang X; Sun X; Li J; Zhang X; Gong T; Zhang Z
    Pharmazie; 2011 Jul; 66(7):496-505. PubMed ID: 21812324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines.
    Coyle T; Levante S; Shetler M; Winfield J
    J Neurooncol; 1994; 19(1):25-35. PubMed ID: 7815102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biodistribution studies of Doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles synthesized by two different techniques.
    Reddy LH; Murthy RS
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Dec; 148(2):161-6. PubMed ID: 15744366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's lymphoma tumour.
    Reddy LH; Sharma RK; Murthy RS
    J Drug Target; 2004; 12(7):443-51. PubMed ID: 15621669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
    Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
    Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colloidal formulations of etoposide based on poly(butyl cyanoacrylate) nanoparticles: preparation, physicochemical properties and cytotoxicity.
    Yordanov G; Skrobanska R; Evangelatov A
    Colloids Surf B Biointerfaces; 2013 Jan; 101():215-22. PubMed ID: 23010022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo.
    Zhu Y; Zhang J; Meng F; Deng C; Cheng R; Feijen J; Zhong Z
    J Control Release; 2016 Jul; 233():29-38. PubMed ID: 27178807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
    Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
    Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.